Salvage lenalidomide in four rare oncological diseases
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F13%3A%230002125" target="_blank" >RIV/65269705:_____/13:#0002125 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/13:00065660 RIV/00209805:_____/13:#0000476
Result on the web
<a href="http://dx.doi.org/10.1700/1377.15326" target="_blank" >http://dx.doi.org/10.1700/1377.15326</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1700/1377.15326" target="_blank" >10.1700/1377.15326</a>
Alternative languages
Result language
angličtina
Original language name
Salvage lenalidomide in four rare oncological diseases
Original language description
In rare disorders, there are often no standard therapy recommendations. Patients with refractory disease may require novel experimental approaches. Applied as second- up to fourth-line treatment, lenalidomide (10-25 mg perorally on days 1-21 in a 28-daycycle) was used in our cohort of four adult patients with aggressive, multisystem and relapsing diseases. Complete and long-lasting remissions (more than 1 year, no maintenance therapy) were achieved in patients with Langerhans cell histiocytosis (11 cycles, combination with dexamethasone and etoposide, consolidated by allogeneic blood stem cell transplant) and plasma-cell Castleman disease (15 cycles, monotherapy). Mixed response with complete disappearance of brain infiltrates was reached in Erdheim-Chester disease (6 cycles, monotherapy) and gastrointestinal bleeding was well controlled in multiple angiomatosis (9 cycles, combination with thalidomide). For disease activity evaluation each patient underwent fluorine-18-fluorodeoxygluc
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Tumori
ISSN
0300-8916
e-ISSN
—
Volume of the periodical
99
Issue of the periodical within the volume
5
Country of publishing house
IT - ITALY
Number of pages
6
Pages from-to
"e251"-"e256"
UT code for WoS article
—
EID of the result in the Scopus database
—